BioCentury | Jul 7, 2020
Deals

Adding to targeted oncology portfolio, Zai gains China rights to Turning Point’s repotrectinib

In its latest cross-border in-licensing deal, Zai gained territorial rights to yet another targeted cancer therapy via a deal with Turning Point for repotrectinib, which is in a pivotal trial that could lead to approvals...
BioCentury | Jun 6, 2020
Management Tracks

COVID-19 vaccine partners Lonza and Moderna announce new execs; plus Samumed, EpicentRx, Immatics, Aligos, ImmunoGen, Ferring, Sanifit and more

Pierre-Alain Ruffieux will become CEO of Lonza Group Ltd. (SIX:LONN), effective Nov. 1. He succeeds Chairman Albert Baehny, who had been serving on an interim basis since former CEO Marc Funk stepped down in January....
BioCentury | Apr 18, 2020
Management Tracks

PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more

Rare diseases company PTC Therapeutics Inc. (NASDAQ:PTCT) promoted Matthew Klein to chief development officer and Eric Pauwels to CBO. Klein was global head of gene and mitochondrial therapies; Pauwels was SVP and general manager of...
BioCentury | Apr 10, 2020
Management Tracks

Shakeup at Arix; plus Emergent, AlloVir, Asklepios Bio, Morphic, Gritstone and more

Arix Bioscience plc (LSE:ARIX) announced a series of senior management departures. CEO Joe Anderson has stepped down as CEO of the healthcare and life science investment company along with two undisclosed members of the senior...
BioCentury | Mar 5, 2020
Finance

Amunix’s Omega-led $73M A round to support shift to drug development

The potential for Amunix’s protein polymer technology to overcome toxicity issues that have plagued two growing immuno-oncology modalities convinced Omega Funds to lead the biotech’s $73 million series A. The round, together with cash from...
BC Extra | Jan 10, 2020
Company News

Management tracks: COO, CMO depart as Solid restructures; plus Abeona, Millendo, Immuneering, Akouos, Kintai, Macrophage, Selexis, Prime

Solid Biosciences Inc. (NASDAQ:SLDB) said COO Alvaro Amorrortu and CMO Chief Jorge Quiroz will step down as the company restructures, reducing its workforce by about one third, to extend its runway. Amorrortu and Quiroz will...
BC Extra | Dec 27, 2019
Company News

Management tracks: Founder Williams leaving Five Prime to focus on start-up Walking Fish; plus Rubius, Replimune, Invicro, Cerecin, SGI-DNA

Cancer company Five Prime Therapeutics Inc. (NASDAQ:FPRX) said founder Lewis “Rusty” Williams will step down from the board to focus on his role as chairman and CEO of Walking Fish Therapeutics Inc. , a cell therapy...
BC Extra | Dec 7, 2019
Financial News

Jasper debuts with $35M series A, licenses antibody from Amgen to prep patients for transplants

With an antibody in-licensed from Amgen and a $35 million series A led by Abingworth and Qiming Venture Partners, Jasper is aiming to make stem cell transplants safer for patients. Surveyor Capital and Alexandria Venture...
BC Extra | Sep 19, 2019
Company News

Management tracks: CASI promotes Zhang to president; plus Five Prime, Black Diamond, Oyster Point, Enyo, X4, Nimbus and Canbridge

Cancer and generics company CASI Pharmaceuticals Inc. (NASDAQ:CASI) promoted Larry Zhang to president. He was president of the cancer and generics company's Chinese subsidiary CASI Pharmaceuticals (Beijing) Co. Ltd. Prior to joining CASI, Zhang was...
BC Extra | Jun 11, 2019
Company News

Ahead of Phase III data, Zai adds Deciphera's GIST candidate to gastric cancer franchise

With a Phase III readout imminent for Deciphera's kinase switch control inhibitor ripretinib in GIST, Zai Lab has obtained the compound's rights in Greater China, adding to a planned gastric cancer franchise it has built...
Items per page:
1 - 10 of 205
BioCentury | Jul 7, 2020
Deals

Adding to targeted oncology portfolio, Zai gains China rights to Turning Point’s repotrectinib

In its latest cross-border in-licensing deal, Zai gained territorial rights to yet another targeted cancer therapy via a deal with Turning Point for repotrectinib, which is in a pivotal trial that could lead to approvals...
BioCentury | Jun 6, 2020
Management Tracks

COVID-19 vaccine partners Lonza and Moderna announce new execs; plus Samumed, EpicentRx, Immatics, Aligos, ImmunoGen, Ferring, Sanifit and more

Pierre-Alain Ruffieux will become CEO of Lonza Group Ltd. (SIX:LONN), effective Nov. 1. He succeeds Chairman Albert Baehny, who had been serving on an interim basis since former CEO Marc Funk stepped down in January....
BioCentury | Apr 18, 2020
Management Tracks

PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more

Rare diseases company PTC Therapeutics Inc. (NASDAQ:PTCT) promoted Matthew Klein to chief development officer and Eric Pauwels to CBO. Klein was global head of gene and mitochondrial therapies; Pauwels was SVP and general manager of...
BioCentury | Apr 10, 2020
Management Tracks

Shakeup at Arix; plus Emergent, AlloVir, Asklepios Bio, Morphic, Gritstone and more

Arix Bioscience plc (LSE:ARIX) announced a series of senior management departures. CEO Joe Anderson has stepped down as CEO of the healthcare and life science investment company along with two undisclosed members of the senior...
BioCentury | Mar 5, 2020
Finance

Amunix’s Omega-led $73M A round to support shift to drug development

The potential for Amunix’s protein polymer technology to overcome toxicity issues that have plagued two growing immuno-oncology modalities convinced Omega Funds to lead the biotech’s $73 million series A. The round, together with cash from...
BC Extra | Jan 10, 2020
Company News

Management tracks: COO, CMO depart as Solid restructures; plus Abeona, Millendo, Immuneering, Akouos, Kintai, Macrophage, Selexis, Prime

Solid Biosciences Inc. (NASDAQ:SLDB) said COO Alvaro Amorrortu and CMO Chief Jorge Quiroz will step down as the company restructures, reducing its workforce by about one third, to extend its runway. Amorrortu and Quiroz will...
BC Extra | Dec 27, 2019
Company News

Management tracks: Founder Williams leaving Five Prime to focus on start-up Walking Fish; plus Rubius, Replimune, Invicro, Cerecin, SGI-DNA

Cancer company Five Prime Therapeutics Inc. (NASDAQ:FPRX) said founder Lewis “Rusty” Williams will step down from the board to focus on his role as chairman and CEO of Walking Fish Therapeutics Inc. , a cell therapy...
BC Extra | Dec 7, 2019
Financial News

Jasper debuts with $35M series A, licenses antibody from Amgen to prep patients for transplants

With an antibody in-licensed from Amgen and a $35 million series A led by Abingworth and Qiming Venture Partners, Jasper is aiming to make stem cell transplants safer for patients. Surveyor Capital and Alexandria Venture...
BC Extra | Sep 19, 2019
Company News

Management tracks: CASI promotes Zhang to president; plus Five Prime, Black Diamond, Oyster Point, Enyo, X4, Nimbus and Canbridge

Cancer and generics company CASI Pharmaceuticals Inc. (NASDAQ:CASI) promoted Larry Zhang to president. He was president of the cancer and generics company's Chinese subsidiary CASI Pharmaceuticals (Beijing) Co. Ltd. Prior to joining CASI, Zhang was...
BC Extra | Jun 11, 2019
Company News

Ahead of Phase III data, Zai adds Deciphera's GIST candidate to gastric cancer franchise

With a Phase III readout imminent for Deciphera's kinase switch control inhibitor ripretinib in GIST, Zai Lab has obtained the compound's rights in Greater China, adding to a planned gastric cancer franchise it has built...
Items per page:
1 - 10 of 205